SEGMENT INFORMATION

12 Months Ended

Oct. 31, 2024

Segment Reporting [Abstract]

SEGMENT INFORMATION

8. SEGMENT INFORMATION

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other. The following represents selected financial information for our segments for the years ended October 31, 2024 and 2023, in thousands:

	Year Ended October 31,
	2024			2023
Net loss:
Cancer Vaccines	$	(7,388	)	$	(5,111	)
CAR-T Therapeutics		(5,256	)	$	(3,879	)
Other		(54	)		(940	)
Total	$	(12,698	)	$	(9,930	)
Total operating costs and expenses	$	13,831		$	11,221
Less non-cash stock-based compensation		(4,782	)		(4,735	)
Operating costs and expenses excluding non-cash stock-based compensation	$	9,049		$	6,486
Operating costs and expenses excluding non-cash stock-based compensation:
Cancer Vaccines	$	5,235		$	3,265
CAR-T Therapeutics		3,766			2,467
Other		48			754
Total	$	9,049		$	6,486

	October 31,
	2024		2023
Total assets:
Cancer Vaccines	$	12,917	$	17,215
CAR-T Therapeutics		8,535		7,523
Other		139		784
Total	$	21,591	$	25,522

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

The Company had no revenue during the year ended October 31, 2024. The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000, for the year ended October 31, 2023 were solely related to our other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.